ctSearch Results
Original Query
What is cancer romidepsin?
Search Results
- cancer romidepsin
Romidepsin is a substance being studied in the treatment of cancer. Romidepsin is a type of depsipeptide and histone deacetylase inhibitor. Also called FR901228. Cancer is a term for diseases in which abnormal cells divide without control and can invade nearby tissues. Cancer cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of cancer. Carcinoma is a cancer that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are cancers that begin in the cells of the immune system. Central nervous system cancers are cancers that begin in the tissues of the brain and spinal cord. Also called malignancy.
Preview- It`s possible to presume that, INTRODUCTION Most epidermal growth factor receptor (EGFR) mutant non-small cell lung cancers (NSCLCs) are sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, but many EGFR wild type NSCLCs are resistant to TKIs. Epidermal growth factor receptor is the protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor. Also called EGFR, ErbB1, and HER1. Kinase is a type of enzyme (a protein that speeds up chemical reactions in the body) that adds chemicals called phosphates to other molecules, such as sugars or proteins. This may cause other molecules in the cell to become either active or inactive. Kinases are a part of many cell processes. Some cancer treatments target certain kinases that are linked to cancer. Gefitinib is a drug that is used to treat certain types of non-small cell lung cancer and is being studied in the treatment of other types of cancer. It is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called Iressa and ZD1839. EGFR is the protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor. Also called epidermal growth factor receptor, ErbB1, and HER1. Cell is the individual unit that makes up the tissues of the body. All living things are made up of one or more cells. Epidermal growth factor is a protein made by many cells in the body and by some types of tumors. It causes cells to grow and differentiate (become more specialized). It is a type of growth factor and a type of cytokine. Also called EGF. Receptor is a molecule inside or on the surface of a cell that binds to a specific substance and causes a specific effect in the cell. Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva. Growth factor is a substance made by the body that functions to regulate cell division and cell survival. Some growth factors are also produced in the laboratory and used in biological therapy. Lung, one of a pair of organs in the chest that supplies the body with oxygen, and removes carbon dioxide from the body.
- You can determine, keywords Erlotinib Romidepsin Non-small cell lung cancer Epidermal growth factor receptor KRAS The epidermal growth factor receptor (EGFR) belongs to the EGFR family of tyrosine kinase receptors.1 Upon activation, EGFR can promote cell proliferation and survival through Ras/ MEK/MAPK and/or PI3K/AKT signaling pathways.2 In recent years, non-small cell lung cancers (NSCLCs) containing EGFR mutations have been found to be sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib (Tarceva) or gefitinib (Iressa), and these drugs have been successfully used in the therapy for such patients.3,4 Unfortunately, some patients with cancers containing EGFR mutations develop resistance to TKIs after a period of time. Although the mechanisms of resistance are not completely understood, the existence of the secondary T790M mutation activity appears to be the major mechanism.5 Furthermore, most of the NSCLCs containing wild type EGFR receptor are resistant to therapy with EGFR TKIs.6 In addition, the presence of KRAS mutations is associated with primary resistance to TKIs.7 Thus, the role of erlotinib and gefitinib for the treatment of NSCLC is limited. Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774. Therapy, treatment. PI3K is a type of enzyme that transmits signals in cells and that helps control cell growth. Some tumors have higher-than-normal levels of PI3K. Also called phosphatidylinositol-3 kinase and PI3 kinase. Akt is a group of enzymes involved in several processes related to cell growth and survival. Akt enzymes help to transfer signals inside cells. An Akt enzyme is a type of serine/threonine protein kinase. Also called protein kinase B. Cell proliferation is an increase in the number of cells as a result of cell growth and cell division. Iressa is a drug that is used to treat certain types of non-small cell lung cancer and is being studied in the treatment of other types of cancer. It is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called gefitinib and ZD1839.
- One can determine, histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD*, Michael Peyton, PhD*, Yang Xie, PhD,, Junichi Soh, MD*, John D. Minna, MD*,,,, Adi F. Histone deacetylase inhibitor is a substance that causes a chemical change that stops tumor cells from dividing. Histone deacetylase inhibitors are being studied in the treatment of cancer. Also called HDAC inhibitor. Histone deacetylase is an enzyme that removes a small molecule called an acetyl group from histones (proteins found in chromosomes). This changes the way the histones bind to DNA and may affect its activity. Histone deacetylase inhibitors are being studied in the treatment of cancer. Also called HDAC. Histone is a type of protein found in chromosomes. Histones bind to DNA, help give chromosomes their shape, and help control the activity of genes. Tumor is an abnormal mass of tissue that results when cells divide more than they should or do not die when they should. Tumors may be benign (not cancer), or malignant (cancer). Also called neoplasm.
NEW: Try our Cancer Expert Fact Search, and get direct access to our Knowledge Base (KB).
Disclaimer: On occasion, search results will contain fragmented, and erroneous (misspelled, incorrect grammar and malformatted) text. It is not possible, for our Bots to automatically correct these, afterall they represent the corpus created by individuals and/or other Bots and who have placed it on the Internet. Keep in mind, Cancer Expert Search is a search engine, and we are required to return search results as closely resembling their original format, when they were discovered by our Bots (including all errors).
